Original Article
Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer
N Engl J Med 1993; 328:1581-1586June 3, 1993
- Abstract
Background and Methods
Women with ductal carcinoma in situ have been treated both by lumpectomy and by lumpectomy followed by radiation therapy, but the benefit of combined therapy is uncertain. A group of 818 women with ductal carcinoma in situ were randomly assigned to undergo lumpectomy or lumpectomy followed by breast irradiation (50 Gy). Sufficient tissue was removed that the margins of the resected specimens were histologically tumor-free. The mean duration of follow-up was 43 months (range, 11 to 86). The principal end point of the study was event-free survival, as defined by the presence of no new ipsilateral or contralateral breast cancers, regional or distant metastases, or other cancers and by no deaths from causes other than cancer.
Results
Five-year event-free survival was better in the women who received breast irradiation (84.4 percent, vs. 73.8 percent for the women treated by lumpectomy alone; P = 0.001). The improvement was due to a reduction in the occurrence of second ipsilateral breast cancers; the incidence of each of the other events was similar in the two groups. Of 391 women treated by lumpectomy alone, ipsilateral breast cancer developed in 64 (16.4 percent); it was noninvasive in 32 and invasive in the remaining 32. Of 399 women treated with lumpectomy and breast irradiation, ipsilateral breast cancer developed in 28 (7.0 percent) (noninvasive in 20 and invasive in 8). The five-year cumulative incidence of second cancers in the ipsilateral breast was reduced by irradiation from 10.4 percent to 7.5 percent for noninvasive cancers and from 10.5 percent to 2.9 percent for invasive cancers (P = 0.055 and P<0.001, respectively).
Conclusions
Breast irradiation after lumpectomy is more appropriate than lumpectomy alone for women with localized ductal carcinoma in situ. .
Media in This Article
Figure 1
Event-free Survival of Women Treated by Lumpectomy (open circle) or Lumpectomy and Radiation Therapy (solid circle).Figure 2
Cumulative Incidence of Noninvasive and Invasive Ipsilateral Breast Cancers and of All Other First Events in Women Treated by Lumpectomy (open circle) or Lumpectomy and Radiation Therapy (solid circle).Article Activity
- Article
Women with intraductal breast cancer (ductal carcinoma in situ) have been treated in many different ways, ranging from local excision of the tumor with or without breast irradiation to unilateral or bilateral mastectomy. Because there is little justification for mastectomy in women with invasive breast cancer,1 the concept that an operation for noninvasive breast cancer should be more radical than one for invasive disease seems paradoxical.
Before the advent of mammography, approximately 3 to 5 percent of new cases of breast cancer involved ductal carcinomas in situ,2,3 most of which were large, palpable masses. Information about the incidence of recurrence after the removal of these tumors was based on studies of women with clinically detectable lesions3-7. As a consequence of mammography, ductal carcinoma in situ is diagnosed more frequently, and a much higher proportion of the tumors are not clinically detectable8.
Because of uncertainty about the most appropriate treatment for women with these tumors, the National Surgical Adjuvant Breast and Bowel Project began a randomized clinical trial in 1985 to test the hypothesis that in women with localized ductal carcinoma in situ that was thought to have been completely removed, lumpectomy (or more accurately, local excision, since most women did not have a palpable mass) plus breast irradiation is more effective than local excision alone in preventing a second cancer in the ipsilateral breast. The initial results from this trial are presented here.
Methods
Selection of Patients
Women with localized ductal carcinoma in situ detected by physical examination or mammography were eligible for the study. Those with a tumor consisting of both ductal carcinoma in situ and lobular carcinoma in situ were also eligible, as were women with multiple lesions in the same breast if one lesion contained ductal carcinoma in situ and the others were histologically benign. Women with tumor-positive axillary nodes on clinical examination were excluded. If axillary dissection was carried out, all the nodes had to be tumor-negative. Also, women with previous cancers were ineligible, except those who had had in situ carcinoma of the cervix or squamous- or basal-cell cancer of the skin.
Within eight weeks after initial biopsy, the women underwent a lumpectomy, with removal of the tumor and a sufficient amount of normal breast tissue that the margins of the resected specimen were histologically tumor-free. Women with a histologic diagnosis of ductal carcinoma in situ whose mammograms showed diffuse microcalcifications were eligible only if histologic examination of tissue containing the microcalcifications demonstrated no tumor. The tumor diagnoses were made by institutional pathologists.
Study Design
Between October 1, 1985, and December 31, 1990, after they had undergone lumpectomy and given informed consent, the women enrolled in the study were randomly assigned to receive either ipsilateral breast irradiation or no radiation therapy. Randomization was carried out at the study biostatistical center with a stratified scheme designed to avoid inequalities in treatment assignment9. The stratification variables were age ( ≤ 49 or >49 years), axillary dissection (performed or not performed), tumor type (ductal carcinoma in situ or ductal carcinoma in situ plus lobular carcinoma in situ), and method of detection (mammography, clinical examination, or both). Initially, all women underwent axillary-node dissection. After June 1987, such dissection became optional because of reports indicating the infrequency of positive axillary nodes in women with this type of tumor10.
Radiation Therapy
Breast irradiation was begun when wound healing permitted, but no later than eight weeks after the operation. The patients received a dose of 50 Gy, calculated at a depth equal to two thirds of the distance between the skin overlying the breast and the base of the tangential fields at midseparation. The dose was given at a rate of 10 Gy per week (2 Gy per day for five days). Nine percent of the women received additional radiation therapy to the tumor site. Interstitial radiation and regional node irradiation were not allowed. The radiation-therapy technique was similar to that used in previous studies11,12.
Follow-up and Identification of Study End Points
Women underwent follow-up examinations every six months; mammography was performed annually. A tumor detected at a local or regional site after the initial operation was considered an event when a biopsy of the lesion was positive. A tumor at a distant site was considered an event when the clinical, radiographic, or pathological findings indicated that tumor was present. The presence of ipsilateral or contralateral breast cancer, regional or distant metastasis, or a second primary tumor other than a breast tumor occurring as a first event after the operation or the patient's death in the absence of evidence of recurrent breast cancer was used to determine event-free survival.
The location of primary tumors and postoperative ipsilateral breast tumors was determined from mammographic, operative, and pathological reports submitted to the biostatistical center. Tumors were classified as being in a specific quadrant, on the border between two quadrants, central (in a subareolar position or at the border of a quadrant and the areola), or diffuse (in more than one of the preceding sites).
Statistical Analysis
The results in the two treatment groups were compared for all randomized patients for whom information was available that could be evaluated. The percentage of women in whom no event occurred was determined with a life-table estimate computed by the actuarial method13. The two treatment groups were compared in relation to the distribution of the time before the occurrence of a first event by means of a two-sided summary chi-square (log-rank) test14. P values and relative odds with 95 percent confidence intervals were determined annually and were designated as cumulative; the values summarized the outcome to the designated time15,16. Two-sided P values less than 0.05 were considered statistically significant.
Average annual incidence rates, relative risks, and 95 percent confidence intervals were calculated for each type of first event. The chi-square test was used to compare the average annual type-specific incidence rates in the treatment groups17. Relative risks and 95 percent confidence intervals were determined by univariate proportional-hazards analysis18. Cumulative incidence rates were plotted for events for which the comparison of treatments revealed a significant difference19. To test for interactions between the stratification variables and treatment in relation to event-free survival, multivariate proportional-hazards analysis was used18. The results presented here represent the first formal testing of the primary study hypothesis as originally planned on the basis of data obtained one year after the accrual of patients into the study.
Results
Distribution of Patients
A total of 818 women were enrolled in the trial (Table 1Table 1
Distribution of Patients According to Treatment Group and Protocol Status.). None of the records obtained at one institution (representing 24 patients) could be evaluated, because of problems with the quality of the data. No follow-up results were available for 4 of the 794 women who could be evaluated (0.5 percent). Sixteen of the 790 women included in the analyses (2.0 percent) did not meet the criteria for study entry. Five years after the operation, follow-up results were up to date for 97.5 percent of the women who could be evaluated. All women who could be evaluated for whom there were follow-up data, including those who did not meet the criteria for entry into the study, were included in the analyses. The mean duration of follow-up was 43 months (range, 11 to 86). There were no differences between treatment groups in the distribution of selected characteristics of the patients and tumors (Table 2Table 2
Characteristics of the Study Patients, According to Treatment Group.).Event-free Survival
The women treated by lumpectomy followed by ipsilateral breast irradiation had significantly better event-free survival during five years of follow-up than the women treated by lumpectomy alone (84.4 percent vs. 73.8 percent, respectively; P = 0.001) (Figure 1Figure 1
Event-free Survival of Women Treated by Lumpectomy (open circle) or Lumpectomy and Radiation Therapy (solid circle).). The cumulative odds ratio of 1.8 (95 percent confidence interval, 1.2 to 2.5) confirmed the beneficial effect of radiation therapy. There was a 47.3 percent reduction in the average annual incidence rate (per 100 women) for all first events (6.7 for lumpectomy alone vs. 3.8 for lumpectomy plus irradiation; P = 0.001) as a result of radiation therapy (Table 3Table 3
Average Annual Incidence of First Events in Each Treatment Group after Operation.). No significant interactions between stratification variables and treatment were identified.First Events in the Ipsilateral Breast
Sixty-four of all 84 first events (76.2 percent) in the group treated by lumpectomy alone were ipsilateral breast tumors, as compared with 28 of 51 first events (54.9 percent) in the group undergoing lumpectomy and radiation therapy (Table 3). The average annual incidence rate of ipsilateral breast cancer was reduced by 58.8 percent as a consequence of radiation therapy (lumpectomy, 5.1; lumpectomy plus radiation, 2.1; P<0.001). The rates of both noninvasive cancers (2.6 and 1.5 in the respective groups; P = 0.055) and invasive cancers (2.6 and 0.6; P<0.001) were reduced, but the percent reduction was greater in the latter (42.3 percent vs. 76.9 percent). There was no reduction in the average annual incidence rate of other types of first events (contralateral breast cancers, other second cancers, and deaths from causes other than cancer) as a result of radiation therapy.
At five years of follow-up, in the women treated by lumpectomy alone, the cumulative incidence of ipsilateral noninvasive and invasive cancers was 10.4 percent and 10.5 percent, respectively, whereas in the group treated by lumpectomy and radiation, it was 7.5 percent and 2.9 percent (Figure 2Figure 2
Cumulative Incidence of Noninvasive and Invasive Ipsilateral Breast Cancers and of All Other First Events in Women Treated by Lumpectomy (open circle) or Lumpectomy and Radiation Therapy (solid circle).). There was no significant difference between the two groups in the cumulative incidence of first events other than ipsilateral breast tumors (6.7 percent and 7.1 percent, respectively). Three of the 92 women in whom second tumors developed in the ipsilateral breast subsequently had distant disease. Two of the three were treated by lumpectomy alone, and cancer subsequently developed in the contralateral breast. The other woman was treated by lumpectomy and radiation, and liver metastases subsequently developed.The location of the primary and second tumors was evaluated in the 83 women in whom the sites of both tumors were known. In 63 women (76.9 percent), either the first and second tumors were within the same quadrant, or one tumor was inside a quadrant and the other was on the border of the same quadrant. In two of the women (2.4 percent), the second tumors were in the same quadrant and extended into other quadrants as well. In seven women (8.4 percent), one of the two tumors was retroareolar; the other was either on the border of a quadrant with the areola or within a quadrant. In 11 women (13.3 percent), the second tumors were located at sites different from those of the primary tumors. Nine of the 11 second tumors were in quadrants different from those of the primary tumors, and in two patients the primary tumor occurred on one border of the quadrant and the second tumor on another border of the same quadrant.
Among the 64 women whose primary ductal carcinoma in situ was treated by lumpectomy only and in whom a second breast tumor developed, 28 (43.8 percent) were treated by repeat lumpectomy and 36 (56.3 percent) by mastectomy. The percentage of women treated by a second local excision was similar regardless of whether the second tumors were noninvasive or invasive (43.8 percent). Twenty-eight women who received radiation therapy to treat their primary tumors had second tumors in the ipsilateral breast. Ten of the 20 who had noninvasive tumors (50 percent) were treated with lumpectomy, and 10 had mastectomies. All eight women whose second tumors were invasive had mastectomies. Six of the 54 women in both groups whose second tumors were treated by mastectomy had a prophylactic mastectomy of the contralateral breast.
Regional and Distant First Events
Few regional and distant events occurred as first events in either treatment group (Table 3). Three women had regional metastases. In two women whose ductal carcinoma in situ was detected from microcalcifications on a mammogram and who were treated by lumpectomy and radiation therapy, ipsilateral node metastasis subsequently developed (one after 15 months and one after 7 months) without evidence of disease in the breast. The third woman, treated by lumpectomy alone, also had ductal carcinoma in situ that was detected from microcalcifications; she had nodal metastases 5 1/2 years later.
Two women had distant metastatic breast cancer. In one of them, treated by lumpectomy alone, the breast cancer was found to have metastasized to her femur, with no evidence of disease in the breast eight months later. The other had concomitant contralateral supraclavicular nodal metastases, liver metastases, and extensive invasive ipsilateral breast cancer 12 months after lumpectomy and radiation therapy. She died one month after the diagnosis of metastasis.
First Events in the Contralateral Breast
Eighteen women, 8 in the lumpectomy group and 10 in the group treated by lumpectomy and radiation, had contralateral breast cancer as a first event. The initial cancer was detected by palpation in 1 woman, nipple discharge in 1, and mammography (revealing microcalcifications) in 16. Eleven of the contralateral breast cancers were invasive, and seven were ductal carcinoma in situ. Fourteen of the 18 contralateral tumors were treated by lumpectomy, 3 by mastectomy, and 1, an inflammatory cancer, by systemic therapy followed by mastectomy.
Second Primary Tumors as First Events
In the group treated by lumpectomy alone, five second cancers exclusive of those in the ipsilateral breast occurred as first events: two in the colon and one each in the pancreas, lung, and skin of the arm. Eight second cancers occurred in women who received radiation therapy: three in the colon and one each in the tonsil, esophagus, uterus, lung, and the skin of the arm.
Death as a First Event
Death from causes other than cancer occurred as a first event in five women in the lumpectomy group and two in the group receiving radiation therapy. One of the 92 women in whom a second ipsilateral breast tumor developed as a first event died of breast cancer. There were only two other deaths from breast cancer. One occurred in the woman who had extensive distant disease and concomitant ipsilateral breast involvement as a first event after lumpectomy and radiation therapy. The other woman who died of breast cancer, also in the group receiving radiation, had supraclavicular nodal metastases as the first event.
Discussion
The results of this randomized trial of therapy in women with ductal carcinoma in situ indicate that radiation therapy after lumpectomy improved overall event-free survival as compared with lumpectomy alone. All first events occurring after the initial therapy were considered in the life-table analysis, ensuring that ipsilateral breast tumors were accounted for and that events that could have been attributed to undesirable sequelae of therapy were included. Moreover, the inclusion of all the first events addressed the problem of competing risks by taking into account women who had metastases to a regional or distant site, had second tumors other than in the ipsilateral breast, or died from other causes before a second ipsilateral breast tumor developed.
The benefit of radiation therapy was most evident when each type of first event was evaluated according to its contribution to the overall effect. As expected, there was no evidence that irradiation reduced the average annual incidence rates or the cumulative incidence of non-cancer-related deaths, second primary cancers (either in the contralateral breast or at other sites), and regional or distant metastatic disease. The benefit of radiation therapy was related to its ability to decrease the cumulative incidence of all second ipsilateral breast tumors as compared with that in the group treated only by lumpectomy. This reduction was evident for both noninvasive and invasive second cancers.
It might be considered that women with ductal carcinoma in situ should be treated by mastectomy, since women treated by lumpectomy alone had a 20.7 percent estimated risk of a second ipsilateral breast tumor. However, since radiation therapy significantly reduced the incidence of both noninvasive and invasive second tumors to 7.5 percent and 2.9 percent, respectively, mastectomy may be difficult to justify to treat localized ductal carcinoma in situ. Furthermore, since the women in whom another ductal carcinoma in situ developed after radiation therapy are likely to have the same prognosis that they had when the first lesion was identified, that contention is strengthened. The development of an invasive lesion after the removal of ductal carcinoma in situ and treatment by radiation therapy, as occurred in 2.9 percent of the women in our study, may be viewed differently. It may be argued that those invasive cancers, with their potential for dissemination, could have been prevented had the primary tumor been treated by mastectomy. If the incidence of such cancers remains low, however, and if they are detected when they are small, few of them should result in distant disease and death20.
Pathologists may have difficulty differentiating between benign breast lesions (e.g., highly atypical hyperplasia) and ductal carcinoma in situ, between ductal carcinoma in situ and lobular carcinoma in situ, and between ductal carcinoma in situ and a focus of invasive cancer, especially when the latter is associated with ductal carcinoma in situ21. In large randomized trials, women with tumors of uncertain type should be equally distributed among the treatment groups, thus eliminating that source of bias. Moreover, the findings from a large trial that includes women who have ductal carcinoma in situ with a focus of invasive tumor should be applicable to the general population of women with ductal carcinoma in situ, some of whom could have tumors with undiagnosed invasive components. A review of slides submitted to the pathology center demonstrated invasive cancers in 1.5 percent of the primary tumors surveyed and atypical hyperplasia in 4.7 percent. The discordance in the diagnosis could have been related at least in part to a sampling error -- i.e., the slides submitted may not have been representative of the material from which the original diagnosis of ductal carcinoma in situ was made. Because the discordant diagnoses were few and were distributed between the two groups of women, they did not affect the conclusions of the study.
After the local excision of ductal carcinoma in situ, second ipsilateral tumors are almost always at or close to the site of the primary tumor21. In this study, 13.3 percent of the second tumors were in a different location, a proportion somewhat higher than is usually reported. Because most information about concordance comes from the study of women with invasive cancer, there may be a difference between noninvasive and invasive tumors in that regard.
In summary, since the incidence of second ipsilateral tumors is significantly reduced by breast irradiation after lumpectomy, combined therapy is more appropriate than lumpectomy alone for women with localized intraductal carcinoma in situ.
Supported by Public Health Service grants from the National Cancer Institute and by grants from the American Cancer Society.
We are indebted to Tanya Spewock for her assistance in the preparation of the manuscript.
Source Information
From the National Surgical Adjuvant Breast and Bowel Project Headquarters, Rm. 914, Scaife Hall, 3550 Terrace St., Pittsburgh, PA 15261, where reprint requests should be addressed to Dr. Fisher.
Institutions contributing 10 or more patients to the study are listed in the Appendix, together with the names of the principal investigators.
Appendix
The following institutions, listed with the names of the principal investigators, each contributed 10 or more patients to this study.
Baptist Medical Center, Oklahoma City: K.K. Boatman; Boston University, Boston: M.T. Kavanah; British Columbia Cancer Agency, Vancouver, Canada: I.H. Plenderleith and I. Olivotto; Community Clinical Oncology Program (CCOP), Allegheny, Pittsburgh: R. Pugh; CCOP, Alton Ochsner Medical Foundation, New Orleans: C.G. Kardinal; CCOP, Columbia River Oncology Program, Portland, Oreg.: G.L. Doty; CCOP, Marshfield Clinic, Marshfield, Wis.: J.L. Hoehn; City of Hope Medical Center, Duarte, Calif.: L.D. Wagman; Good Samaritan Hospital, Cincinnati: R. Welling; Hartford Hospital, Hartford, Conn.: P.A. DeFusco; Hotel-Dieu, Montreal: A. Robidoux; Jewish General Hospital, Montreal: R.G. Margolese; Kaiser Permanente, Portland, Oreg.: A.G. Glass; Medical College of Wisconsin, Milwaukee: A.P. Walker; Michigan State University, E. Lansing, Mich.: N.V. Dimitrov; Mount Sinai Medical Center, Cleveland: R. Bornstein and L. Levy; Pennsylvania Hospital, Philadelphia: H.J. Lerner; St. Michael's Hospital, Toronto: L. Mahoney; Tufts University-New England Medical Center, Boston: D.D. Karp; University of California, Los Angeles: A.E. Giuliano; University of Hawaii, Honolulu: R. Oishi; University of Michigan, Ann Arbor: B.L. Weber; and University of Pittsburgh, Pittsburgh: B. Fisher.
- References
References
1
Fisher B ,Redmond C ,Poisson R , et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-828
Full Text | Web of Science | Medline2
Rosner D ,Bedwani RN ,Vana J ,Baker HW ,Murphy GP . Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139-147
CrossRef | Web of Science | Medline3
Lagios MD ,Westdahl PR ,Margolin FR ,Rose MR . Duct carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982;50:1309-1314
CrossRef | Web of Science | Medline4
Zafrani B ,Fourquet A ,Vilcoq JR ,Legal M ,Calle R . Conservative management of intraductal breast carcinoma with tumorectomy and radiation therapy. Cancer 1986;57:1299-1301
CrossRef | Web of Science | Medline5
Recht A ,Danoff BS ,Solin LJ , et al. Intraductal carcinoma of the breast: results of treatment with excisional biopsy and irradiation. J Clin Oncol 1985;3:1339-1343
Web of Science | Medline6
Brown PW ,Silverman J ,Owens E ,Tabor DC ,Terz JJ ,Lawrence W Jr . Intraductal “noninfiltrating” carcinoma of the breast. Arch Surg 1976;111:1063-1067
Web of Science | Medline7
Ashikari R ,Hajdu SI ,Robbins GF . Intraductal carcinoma of the breast (1960-1969). Cancer 1971;28:1182-1187
CrossRef | Web of Science | Medline8
Stomper PC ,Connolly JL . Ductal carcinoma in situ of the breast: correlation between mammographic calcification and tumor subtype. AJR Am J Roentgenol 1992;159:483-485
Web of Science | Medline9
Efron B . Forcing a sequential experiment to be balanced. Biometrika 1971;58:403-417
CrossRef | Web of Science10
Silverstein MJ ,Rosser RJ ,Gierson ED , et al. Axillary lymph node dissection for intraductal breast carcinoma -- is it indicated? Cancer 1987;59:1819-1824
CrossRef | Web of Science | Medline11
Fisher B ,Bauer M ,Margolese R , et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-673
Full Text | Web of Science | Medline12
Fisher B ,Wolmark N ,Fisher ER ,Deutsch M . Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations. World J Surg 1985;9:692-698
CrossRef | Web of Science | Medline13
Cutler SJ ,Ederer F . Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958;8:699-712
CrossRef | Medline14
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline15
Robins J ,Breslow N ,Greenland S . Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986;42:311-323
CrossRef | Web of Science | Medline16
Mantel N ,Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748
Web of Science | Medline17
Hypothesis-testing procedures. In: Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning, 1982:284-8.
18
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22019
Korn EL ,Dorey FJ . Applications of crude incidence curves. Stat Med 1992;11:813-829
CrossRef | Web of Science | Medline20
Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. In: National Institutes of Health Consensus Development Conference on the Treatment of Early-Stage Breast Cancer. NCI monographs. No. 11. Washington, D.C.: Government Printing Office, 1992:105-16. (NIH publication no. 90-3187.)
21
Fisher ER ,Sass R ,Fisher B ,Wickerham L ,Paik SM . Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986;57:197-208
CrossRef | Web of Science | Medline
- Citing Articles (283)
Citing Articles
1
Isaac Schmale, Stephen Liu, Jessica Rayhanabad, Christy A. Russell, Stephen F. Sener. (2012) Ductal carcinoma in situ (DCIS) of the breast: Perspectives on biology and controversies in current management. Journal of Surgical Oncology 105:2, 212-220
CrossRef2
Sanaz A. Jansen. (2011) Ductal Carcinoma In Situ: Detection, Diagnosis, and Characterization with Magnetic Resonance Imaging. Seminars in Ultrasound, CT, and MRI 32:4, 306-318
CrossRef3
Jessica L. Keto, Laurie Kirstein, Diana P. Sanchez, Tamara Fulop, Laura McPartland, Ilona Cohen, Susan K. Boolbol. (2011) MRI Versus Breast-Specific Gamma Imaging (BSGI) in Newly Diagnosed Ductal Cell Carcinoma-in-situ: A Prospective Head-to-Head Trial. Annals of Surgical Oncology
CrossRef4
Gabriel Farante, Stefano Zurrida, Viviana Galimberti, Paolo Veronesi, Giuseppe Curigliano, Alberto Luini, Aron Goldhirsch, Umberto Veronesi. (2011) The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. Breast Cancer Research and Treatment 128:2, 369-378
CrossRef5
Jo Anne Zujewski, Linda C. Harlan, Donna M. Morrell, Jennifer L. Stevens. (2011) Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Research and Treatment 127:1, 251-257
CrossRef6
Christopher Herbert, Alan Nichol, Ivo Olivotto, Lorna Weir, Ryan Woods, Caroline Speers, Pauline Truong, Scott Tyldesley. (2011) The Impact of Hypofractionated Whole Breast Radiotherapy on Local Relapse in Patients with Grade 3 Early Breast Cancer: A Population-based Cohort Study. International Journal of Radiation Oncology*Biology*Physics
CrossRef7
I. L. Wapnir, J. J. Dignam, B. Fisher, E. P. Mamounas, S. J. Anderson, T. B. Julian, S. R. Land, R. G. Margolese, S. M. Swain, J. P. Costantino, N. Wolmark. (2011) Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. JNCI Journal of the National Cancer Institute 103:6, 478-488
CrossRef8
Sabin B. Motwani, Sharad Goyal, Meena S. Moran, Arpit Chhabra, Bruce G. Haffty. (2011) Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: A comparison with ECOG study 5194. Cancer 117:6, 1156-1162
CrossRef9
Kirby I. Bland. (2011) William Hunter Harridge Lecture: Contemporary management of pre-invasive and early breast cancer. The American Journal of Surgery 201:3, 279-289
CrossRef10
Celia P. Kaplan, Anna M. Nápoles, E. Shelley Hwang, Joan Bloom, Susan Stewart, Dana Nickleach, Leah Karliner. (2011) Selection of Treatment Among Latina and Non-Latina White Women with Ductal Carcinoma in Situ. Journal of Women's Health 20:2, 215-223
CrossRef11
Kim Bouillon, Nadia Haddy, Suzette Delaloge, Jean-Remy Garbay, Jerome-Philippe Garsi, Pauline Brindel, Abdeddahir Mousannif, Monique G. Lê, Martine Labbe, Rodrigo Arriagada, Eric Jougla, Jean Chavaudra, Ibrahima Diallo, Carole Rubino, Florent de Vathaire. (2011) Long-Term Cardiovascular Mortality After Radiotherapy for Breast Cancer. Journal of the American College of Cardiology 57:4, 445-452
CrossRef12
Nicholas Navin, James Hicks. (2011) Future medical applications of single-cell sequencing in cancer. Genome Medicine 3:5, 31
CrossRef13
Elaine S. Wai, Mary L. Lesperance, Cheryl S. Alexander, Pauline T. Truong, Patrizia Moccia, Matthew Culp, Jennifer Lindquist, Ivo A. Olivotto. (2011) Predictors of Local Recurrence in a Population-Based Cohort of Women with Ductal Carcinoma In Situ Treated with Breast Conserving Surgery Alone. Annals of Surgical Oncology 18:1, 119-124
CrossRef14
Christelle Faure. 2011. Carcinome canalaire in situ du sein. , 117-120.
CrossRef15
Ying Liu, Maria Pérez, Mario Schootman, Rebecca L. Aft, William E. Gillanders, Matthew J. Ellis, Donna B. Jeffe. (2010) A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Research and Treatment 124:3, 835-844
CrossRef16
, Diana S. M. Buist, Linn A. Abraham, William E. Barlow, Arun Krishnaraj, Regan C. Holdridge, Edward A. Sickles, Patricia A. Carney, Karla Kerlikowske, Berta M. Geller. (2010) Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Research and Treatment 124:3, 863-873
CrossRef17
Laura G. Estévez, Isabel Álvarez, Miguel Ángel Seguí, Monserrat Muñoz, Mireia Margelí, Cristina Miró, Carmen Rubio, Ana Lluch, Ignasi Tusquets. (2010) Current perspectives of treatment of ductal carcinoma in situ. Cancer Treatment Reviews 36:7, 507-517
CrossRef18
Shi-Yi Wang, Karen Kuntz, Todd Tuttle, Robert Kane. (2010) Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research and Treatment 124:2, 393-402
CrossRef19
Laura Bauman, Richard J. Barth, Kari M. Rosenkranz. (2010) Breast Conservation in Women with Multifocal-Multicentric Breast Cancer: Is It Feasible?. Annals of Surgical Oncology 17:S3, 325-329
CrossRef20
(2010) Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast. JNCI Monographs 2010:41, 162-177
CrossRef21
Laleh G. Melstrom, Kurt A. Melstrom, Edward C. Wang, Melissa Pilewskie, David J. Winchester. (2010) Ductal Carcinoma In Situ. American Journal of Clinical Oncology 33:5, 438-442
CrossRef22
T. Shamliyan, S.-Y. Wang, B. A. Virnig, T. M. Tuttle, R. L. Kane. (2010) Association Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ. JNCI Monographs 2010:41, 121-129
CrossRef23
Charles J Rosser, Steve Goodison. (2010) Research Highlights. Biomarkers in Medicine 4:4, 495-497
CrossRef24
H. Sackey, K. Sandelin, J. Frisell, M. Wickman, Y. Brandberg. (2010) Ductal carcinoma in situ of the breast. Long-term follow-up of health-related quality of life, emotional reactions and body image. European Journal of Surgical Oncology (EJSO) 36:8, 756-762
CrossRef25
S E Pinder, C Duggan, I O Ellis, J Cuzick, J F Forbes, H Bishop, I S Fentiman, W D George. (2010) A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. British Journal of Cancer 103:1, 94-100
CrossRef26
K. Kerlikowske, A. M. Molinaro, M. L. Gauthier, H. K. Berman, F. Waldman, J. Bennington, H. Sanchez, C. Jimenez, K. Stewart, K. Chew, B. M. Ljung, T. D. Tlsty. (2010) Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis. JNCI Journal of the National Cancer Institute 102:9, 627-637
CrossRef27
B. A. Virnig, T. M. Tuttle, T. Shamliyan, R. L. Kane. (2010) Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. JNCI Journal of the National Cancer Institute 102:3, 170-178
CrossRef28
Isabella Castellano, Caterina Marchiò, Mariano Tomatis, Antonio Ponti, Denise Casella, Simonetta Bianchi, Vania Vezzosi, Riccardo Arisio, Francesca Pietribiasi, Alfonso Frigerio, Maria Piera Mano, Umberto Ricardi, Elena Allia, Valeria Accortanzo, Antonio Durando, Giovanni Bussolati, Tibor Tot, Anna Sapino. (2010) Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. Modern Pathology 23:2, 260-269
CrossRef29
L.W. Cuttino. (2010) American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in-situ subset analysis—4-year data in 194 treated lesions. Breast Diseases: A Year Book Quarterly 21:1, 60-62
CrossRef30
Aimee M. Crago, Michelle Azu, Shannon Tierney, Monica Morrow. (2010) Randomized Clinical Trials in Breast Cancer. Surgical Oncology Clinics of North America 19:1, 33-58
CrossRef31
Jennifer L. Peterson, Laura A. Vallow, Stephanie L. Hines, Steven J. Buskirk. (2009) Ductal carcinoma in situ of the breast. Oncology Reviews 3:4, 237-246
CrossRef32
Laura C. Collins, Ninah Achacoso, Larissa Nekhlyudov, Suzanne W. Fletcher, Reina Haque, Charles P. Quesenberry, Balaram Puligandla, Najeeb S. Alshak, Lynn C. Goldstein, Allen M. Gown, Stuart J. Schnitt, Laurel A. Habel. (2009) Relationship Between Clinical and Pathologic Features of Ductal Carcinoma In Situ and Patient Age. The American Journal of Surgical Pathology 33:12, 1802-1808
CrossRef33
Tsz Ting Law, Ava Kwong. (2009) Surgical Margins in Breast Conservation Therapy: How Much Should We Excise?. Southern Medical Journal 102:12, 1234-1237
CrossRef34
Michael Lagios. (2009) Therapeutic Decisions for Ductal Carcinoma In Situ: A Gordian Knot. The Breast Journal 15:2, 117-119
CrossRef35
Jennifer A. Ligibel, Ann Partridge, Anita Giobbie-Hurder, Mehra Golshan, Karen Emmons, Eric P. Winer. (2009) Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ. Annals of Surgical Oncology 16:1, 106-112
CrossRef36
NOEL WEIDNER, Farnaz Hasteh. 2009. Breast. , 549-634.
CrossRef37
Alberto Costa, Vittorio Zanini. (2008) Precancerous lesions of the breast. Nature Clinical Practice Oncology 5:12, 700-704
CrossRef38
Heather Taffet Gold, Huong T. Do, Andrew W. Dick. (2008) Correlates and effect of suboptimal radiotherapy in women with ductal carcinoma in situ or early invasive breast cancer. Cancer 113:11, 3108-3115
CrossRef39
Melvin J Silverstein. (2008) Ductal carcinoma in situ of the breast: 11 reasons to consider treatment with excision alone. Women's Health 4:6, 565-577
CrossRef40
Ian S Fentiman. (2008) Ductal carcinoma in situ of the breast: one reason for considering radiotherapy as part of breast-conservation therapy. Women's Health 4:6, 579-581
CrossRef41
Kaire Innos, Pamela L. Horn-Ross. (2008) Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment 111:3, 531-540
CrossRef42
Angela L.W. Meisner, M. Houman Fekrazad, Melanie E. Royce. (2008) Breast Disease: Benign and Malignant. Medical Clinics of North America 92:5, 1115-1141
CrossRef43
Rachel E. Ellsworth, Amy Vertrees, Brad Love, Jeffrey A. Hooke, Darrell L. Ellsworth, Craig D. Shriver. (2008) Chromosomal Alterations Associated with the Transition from In Situ to Invasive Breast Cancer. Annals of Surgical Oncology 15:9, 2519-2525
CrossRef44
Csaba Polgár, Zsolt Orosz, Zsuzsanna Kahán, Gabriella Gábor, Nóra Jani, Gábor Cserni, Janaki Hadijev, Janina Kulka, Zoltán Sulyok, Gábor Boross, György Lázár, Zsolt László, Csaba Diczházi, Nóra Udvarhelyi, Éva Szabó, Zoltán Péntek, Tibor Major, János Fodor. (2008) In situ duktális emlőkarcinóma kombinált sebészi- és sugárkezelése: a magyarországi multicentrikus prospektív. Magyar Onkológia 52:3, 269-277
CrossRef45
Nicholas W. Clavin, John Fernandez, Björn H. Schönmeyr, Marc A. Soares, Babak J. Mehrara. (2008) Fractionated Doses of Ionizing Radiation Confer Protection to Mesenchymal Stem Cell Pluripotency. Plastic and Reconstructive Surgery 122:3, 739-748
CrossRef46
D Robinson, L Holmberg, H Møller. (2008) The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. British Journal of Cancer 99:4, 611-615
CrossRef47
S.M. MacDonald, B.N. Napolitano. (2008) Long-Term Results of Conservative Surgery and Radiotherapy for Ductal Carcinoma In Situ Using Lung Density Correction: The Unversity of Michigan Experience. Breast Diseases: A Year Book Quarterly 19:2, 175-176
CrossRef48
Salomone Saverio, Fausto Catena, Donatella Santini, Luca Ansaloni, Tommaso Fogacci, Stefano Mignani, Antonio Leone, Filippo Gazzotti, Stefano Gagliardi, Angelo Cataldis, Mario Taffurelli. (2008) 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Research and Treatment 109:3, 405-416
CrossRef49
Csaba Polgár, Zsuzsanna Kahán, Zsolt Orosz, Gabriella Gábor, Janaki Hadijev, Gábor Cserni, Janina Kulka, Nóra Jani, Zoltán Sulyok, György Lázár, Gábor Boross, Csaba Diczházi, Éva Szabó, Zsolt László, Zoltán Péntek, Tibor Major, János Fodor. (2008) The Role of Radiotherapy in the Conservative Treatment of Ductal Carcinoma in Situ of the Breast. Pathology & Oncology Research 14:2, 179-192
CrossRef50
C. Matuschek, W. Budach. (2008) Strahlentherapie des Mammakarzinoms. Der Onkologe 14:5, 497-503
CrossRef51
(2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet 371:9618, 1098-1107
CrossRef52
Benjamin D Smith, Grace L Smith, Thomas A Buchholz. (2008) Controversies over the role of radiation therapy for ductal carcinoma in situ. Expert Review of Anticancer Therapy 8:3, 433-441
CrossRef53
Esther W. L. Chuwa, Vincent H. S. Tan, Puay-Hoon Tan, Wei-Sean Yong, Guy-Hui Ho, Chow-Yin Wong. (2008) TREATMENT FOR DUCTAL CARCINOMA IN SITU IN AN ASIAN POPULATION: OUTCOME AND PROGNOSTIC FACTORS. ANZ Journal of Surgery 78:1-2, 42-48
CrossRef54
Arjan P. Schouten van der Velden, Roel van Vugt, Jos A.A.M. Van Dijck, Jan Willem H. Leer, Theo Wobbes. (2007) Local Recurrences After Different Treatment Strategies for Ductal Carcinoma In Situ of the Breast: A Population-Based Study in the East Netherlands. International Journal of Radiation Oncology*Biology*Physics 69:3, 703-710
CrossRef55
Arash Naeim, Rishi Sawhney, Catherine H. MacLean, Homayoon Sanati. (2007) Quality Indicators for the Care of Breast Cancer in Vulnerable Elders. Journal of the American Geriatrics Society 55, S258-S269
CrossRef56
S. Pruthi, K. R. Brandt, A. C. Degnim, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, G. K. Dy, J. N. Ingle. (2007) A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and Diagnosis. Mayo Clinic Proceedings 82:8, 999-1012
CrossRef57
Thomas B. Julian, Stephanie R. Land, Virginie Fourchotte, Sarah R. Haile, Edwin R. Fisher, Eleftherios P. Mamounas, Joseph P. Costantino, Norman Wolmark. (2007) Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS?. Annals of Surgical Oncology 14:8, 2202-2208
CrossRef58
American College of Radiology. (2007) Practice Guideline for the Management of Ductal Carcinoma In-Situ of the Breast (DCIS). Journal of the American College of Surgeons 205:1, 145-161.e3
CrossRef59
Merav A. Ben-David, David E. Sturtz, Kent A. Griffith, Kathye R. Douglas, James A. Hayman, Allen S. Lichter, Lori J. Pierce. (2007) Long-Term Results of Conservative Surgery and Radiotherapy for Ductal Carcinoma In Situ Using Lung Density Correction: The University of Michigan Experience. The Breast Journal 13:4, 392-400
CrossRef60
Melvin J. Silverstein, Michael D. Lagios. (2007) Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy?. Journal of Surgical Oncology 95:8, 605-609
CrossRef61
William E. Sumner, Leonidas G. Koniaris, Sarah E. Snell, Seth Spector, Jodeen Powell, Eli Avisar, Frederick Moffat, Alan S. Livingstone, Dido Franceschi. (2007) Results of 23,810 Cases of Ductal Carcinoma-in-situ. Annals of Surgical Oncology 14:5, 1638-1643
CrossRef62
A.P. Schouten van der Velden, J.A.A.M. Van Dijck, Th. Wobbes. (2007) Variations in treatment of ductal carcinoma in situ of the breast: A population-based study in the East Netherlands. European Journal of Surgical Oncology (EJSO) 33:4, 424-429
CrossRef63
Lisa A. Newman, Eleftherios P. Mamounas. (2007) Review of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project. Surgical Clinics of North America 87:2, 279-305
CrossRef64
Tracey Irvine, Ian S Fentiman. (2007) Biology and treatment of ductal carcinoma in situ. Expert Review of Anticancer Therapy 7:2, 135-145
CrossRef65
Eileen Rakovitch, Jean-Philippe Pignol, Carole Chartier, Wedad Hanna, Hariette Kahn, John Wong, Verna Mai, Lawrence Paszat. (2007) The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Research and Treatment 101:3, 335-347
CrossRef66
J. Chakrabarti, A.J. Evans, J. James, I.O. Ellis, S.E. Pinder, R.D. Macmillan. (2006) Accuracy of mammography in predicting histological extent of ductal carcinoma in situ (DCIS). European Journal of Surgical Oncology (EJSO) 32:10, 1089-1092
CrossRef67
Laura A. Lee, Melvin J. Silverstein, Cathie T. Chung, Heather Macdonald, Premal Sanghavi, Melinda Epstein, Dennis R. Holmes, Howard Silberman, Wei Ye, Michael D. Lagios. (2006) Breast cancer–specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. The American Journal of Surgery 192:4, 416-419
CrossRef68
B. D. Smith, B. G. Haffty, T. A. Buchholz, G. L. Smith, D. H. Galusha, J. E. Bekelman, C. P. Gross. (2006) Effectiveness of Radiation Therapy in Older Women With Ductal Carcinoma In Situ. JNCI Journal of the National Cancer Institute 98:18, 1302-1310
CrossRef69
I Soerjomataram, W J Louwman, M J C van der Sangen, R M H Roumen, J W W Coebergh. (2006) Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. British Journal of Cancer 95:3, 393-397
CrossRef70
Giampiero Ausili Cèfaro, Domenico Genovesi, Rita Marchese, Lucia Anna Ursini, Ettore Cianchetti, Enzo Ballone, Marta Di Nicola. (2006) Predictors of local recurrence after conservative surgery and whole-breast irradiation. Breast Cancer Research and Treatment 98:3, 329-335
CrossRef71
D. Lawrence Wickerham, Joseph P. Costantino, Eleftherios P. Mamounas, Thomas B. Julian. (2006) The Landmark Surgical Trials of the National Surgical Adjuvant Breast and Bowel Project. World Journal of Surgery 30:7, 1138-1146
CrossRef72
Arjan P. Schouten Velden, Petra H. M. Peeters, Veronica C. M. Koot, Adriaan Hennipman. (2006) Local Recurrences After Conservative Treatment of Ductal Carcinoma-In-Situ of the Breast Without Radiotherapy: The Effect of Age. Annals of Surgical Oncology 13:7, 990-998
CrossRef73
Angela Katz, Irene Gage, Sheila Evans, Margaret Shaffer, Thomas Fleury, Frederick P. Smith, Richard Flax, Cynthia Drogula, Peter Petrucci, Colette Magnant. (2006) Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. The American Journal of Surgery 191:6, 761-766
CrossRef74
H.-J. Ochel. (2006) A simple measure of reliability in clinical trials of surgical adjuvant radiotherapy. European Journal of Surgical Oncology (EJSO) 32:4, 395-399
CrossRef75
Sue A. Joslyn. (2006) Ductal Carcinoma in Situ: Trends in Geographic, Temporal, and Demographic Patterns of Care and Survival. The Breast Journal 12:1, 20-27
CrossRef76
Victoria White, Myee Pruden, Graham Giles, Paul Kitchen, John Collins, Graeme Inglis, David Hill. (2006) CHANGES IN THE MANAGEMENT OF DUCTAL CARCINOMA IN SITU BEFORE THE RELEASE OF CLINICAL PRACTICE RECOMMENDATIONS IN AUSTRALIA: THE CASE IN VICTORIA. ANZ Journal of Surgery 76:1-2, 28-34
CrossRef77
Andrew P. Feinberg, Rolf Ohlsson, Steven Henikoff. (2006) The epigenetic progenitor origin of human cancer. Nature Reviews Genetics 7:1, 21-33
CrossRef78
Linda J. Adepoju, W. Fraser Symmans, Gildy V. Babiera, S. Eva Singletary, Banu Arun, Nour Sneige, Lajos Pusztai, Thomas A. Buchholz, Aysegul Sahin, Kelly K. Hunt, Funda Meric-Bernstam, Merrick I. Ross, Frederick C. Ames, Henry M. Kuerer. (2006) Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106:1, 42-50
CrossRef79
Kerry James, Kirsten Gielty, Luminita Nica. (2005) Breast Radiotherapy: An Overview of Available Radiation Treatment Options and Treatment Induced Sequelae. Canadian Journal of Medical Radiation Technology 36:4, 37-43
CrossRef80
Jennifer H. Menell, Elizabeth A. Morris, D. David Dershaw, Andrea F. Abramson, Edi Brogi, Laura Liberman. (2005) Determination of the Presence and Extent of Pure Ductal Carcinoma in Situ by Mammography and Magnetic Resonance Imaging. The Breast Journal 11:6, 382-390
CrossRef81
Heather R. MacDonald, Melvin J. Silverstein, Helen Mabry, Brenda Moorthy, Wei Ye, Melinda S. Epstein, Dennis Holmes, Howard Silberman, Michael Lagios. (2005) Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. The American Journal of Surgery 190:4, 521-525
CrossRef82
Fabio Levi, Lalao Randimbison, Van-Cong Te, Carlo La Vecchia. (2005) Invasive breast cancer following ductal and lobular carcinomain situ of the breast. International Journal of Cancer 116:5, 820-823
CrossRef83
Ingrid Idvall, Anita Ringberg, Harald Anderson, Måns Åkerman, Mårten Fernö. (2005) Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast—a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours. The Breast 14:4, 290-297
CrossRef84
Bernard Fisher. 2005. National Surgical Adjuvant Breast and Bowel Project. .
CrossRef85
Feng Wu, Zhi-Biao Wang, Hui Zhu, Wen-Zhi Chen, Jian-Zhong Zou, Jin Bai, Ke-Quan Li, Cheng-Bing Jin, Fang-Lin Xie, Hai-Bing Su. (2005) Extracorporeal high intensity focused ultrasound treatment for patients with breast cancer. Breast Cancer Research and Treatment 92:1, 51-60
CrossRef86
Jeanne S. Mandelblatt, Clyde B. Schechter, K. Robin Yabroff, William Lawrence, James Dignam, Martine Extermann, Sarah Fox, Gretchen Orosz, Rebecca Silliman, Jennifer Cullen, Lodovico Balducci, . (2005) Toward Optimal Screening Strategies for Older Women. Costs, Benefits, and Harms of Breast Cancer Screening by Age, Biology, and Health Status. Journal of General Internal Medicine 20:6, 487-496
CrossRef87
Anne Marie Wallace, Bruce L. Daniel, Stefanie S. Jeffrey, Robyn L. Birdwell, Kent W. Nowels, Frederick M. Dirbas, Pamela Schraedley-Desmond, Debra M. Ikeda. (2005) Rates of reexcision for breast cancer after magnetic resonance imaging-guided bracket wire localization. Journal of the American College of Surgeons 200:4, 527-537
CrossRef88
Tara L. Huston, Rache M. Simmons. (2005) Locally recurrent breast cancer after conservation therapy. The American Journal of Surgery 189:2, 229-235
CrossRef89
Ji-Young Jang, Mi-Ryeong Ryu, Sung-Whan Kim, Chul-Seung Kay, Yeon-Sil Kim, Yoon-Kyeong Oh, Hyung-Chul Kwon, Sei-Chul Yoon, Woo-Chan Park, Byung-Joo Song, Se-Jeong Oh, Sang-Seol Jung, Jong-Man Won, Seung-Nam Kim, Su-Mi Chung. (2005) Clinical Experience of Patients with Ductal Carcinoma In Situ of the Breast Treated with Breast-Conserving Surgery plus Radiotherapy: A Preliminary Report. Cancer Research and Treatment 37:6, 344
CrossRef90
Max Mano, Ghislaine Fraser, Pauline McIlroy, Lynne Stirling, Helen MacKay, Diana Ritchie, Peter Canney. (2005) Locally advanced breast cancer in octogenarian women. Breast Cancer Research and Treatment 89:1, 81-90
CrossRef91
Ph. Meijnen, E. J. Th. Rutgers. (2004) Ductal carcinoma in situ of the breast – an overview of the randomized clinical trials. Breast Cancer Online 7:12,
CrossRef92
Elizabeth Ceilley, Reshma Jagsi, Saveli Goldberg, Lisa Kachnic, Simon Powell, Alphonse Taghian. (2004) The management of ductal carcinoma in situ in North America and Europe. Cancer 101:9, 1958-1967
CrossRef93
L. A. Habel, J. J. Dignam, S. R. Land, M. Salane, A. M. Capra, T. B. Julian. (2004) Mammographic Density and Breast Cancer After Ductal Carcinoma In Situ. JNCI Journal of the National Cancer Institute 96:19, 1467-1472
CrossRef94
Eileen Rakovitch, Alina Mihai, Jean-Philippe Pignol, Wedad Hanna, Jennifer Kwinter, Carole Chartier, Ida Ackerman, John Kim, Kathleen Pritchard, Lawrence Paszat. (2004) Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?. Breast Cancer Research and Treatment 87:3, 265-272
CrossRef95
MF Borg. (2004) Breast-conserving therapy in young women with invasive carcinoma of the breast. Australasian Radiology 48:3, 376-382
CrossRef96
N. N. Baxter. (2004) RESPONSE: Re: Trends in the Treatment of Ductal Carcinoma In Situ of the Breast. JNCI Journal of the National Cancer Institute 96:16, 1259-1260
CrossRef97
G. F. Schwartz, M. D. Lagios, M. J. Silverstein. (2004) Re: Trends in the Treatment of Ductal Carcinoma In Situ of the Breast. JNCI Journal of the National Cancer Institute 96:16, 1258-1259
CrossRef98
G. D. Leonard, S. M. Swain. (2004) Ductal Carcinoma In Situ, Complexities and Challenges. JNCI Journal of the National Cancer Institute 96:12, 906-920
CrossRef99
H. T. Gold, A. W. Dick. (2004) Re: Trends in the Treatment of Ductal Carcinoma In Situ of the Breast. JNCI Journal of the National Cancer Institute 96:11, 887-888
CrossRef100
Alexander R. Miller, Guillermo Brandao, Thomas J. Prihoda, Cheryl Hill, Anatolio B. Cruz, I-Tien Yeh. (2004) Positive margins following surgical resection of breast carcinoma: Analysis of pathologic correlates. Journal of Surgical Oncology 86:3, 134-140
CrossRef101
Dennis B. Cornfield, Juan P. Palazzo, Gordon F. Schwartz, Shanth A. Goonewardene, Albert J. Kovatich, Inna Chervoneva, Terry Hyslop, Roland Schwarting. (2004) The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast. Cancer 100:11, 2317-2327
CrossRef102
Burstein, Harold J., Polyak, Kornelia, Wong, Julia S., Lester, Susan C., Kaelin, Carolyn M., . (2004) Ductal Carcinoma in Situ of the Breast. New England Journal of Medicine 350:14, 1430-1441
Full Text103
S. Roka, M. Rudas, S. Taucher, P. Dubsky, T. Bachleitner-Hofmann, D. Kandioler, M. Gnant, R. Jakesz. (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. European Journal of Surgical Oncology (EJSO) 30:3, 243-247
CrossRef104
N. N. Baxter, B. A. Virnig, S. B. Durham, T. M. Tuttle. (2004) Trends in the Treatment of Ductal Carcinoma In Situ of the Breast. JNCI Journal of the National Cancer Institute 96:6, 443-448
CrossRef105
Heather Taffet Gold, Andrew W. Dick. (2004) Variations in Treatment for Ductal Carcinoma In Situ in Elderly Women. Medical Care 42:3, 267-275
CrossRef106
Laura Esserman, Karen Sepucha, Elissa Ozanne, E. Shelley Hwang. (2004) Applying the neoadjuvant paradigm to ductal carcinoma in situ. Annals of Surgical Oncology 11:S1, 28S-36S
CrossRef107
Melvin J Silverstein, Claire Buchanan. (2003) Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. The Breast 12:6, 457-471
CrossRef108
Elizabeth B Claus, Meredith Stowe, Darryl Carter, Theodore Holford. (2003) The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. The Breast 12:6, 451-456
CrossRef109
Cyrus Kotwall, Carla Brinker, Debra Covington, Tana Hall, Mary Sue Hamann, J.Gary Maxwell, Anquonette Stiles, Anna Weiss. (2003) Local and national trends over a decade in the surgical treatment of ductal carcinoma in situ. The American Journal of Surgery 186:6, 723-729
CrossRef110
G Sakorafas. (2003) Optimal management of ductal carcinoma in situ of the breast. Surgical Oncology 12:4, 221-240
CrossRef111
Timothy W. Jacobs. (2003) Recently Recognized Variants of Lobular Carcinoma In Situ (LCIS) With an Emphasis on Management of LCIS on Core Needle Biopsy. Pathology Case Reviews 8:5, 211-219
CrossRef112
Faina Nakhlis, Monica Morrow. (2003) Ductal carcinoma in situ. Surgical Clinics of North America 83:4, 821-839
CrossRef113
Melvin J Silverstein. (2003) Current controversies in ductal carcinoma in situ of the breast:. Journal of the American College of Surgeons 197:1, 115-118
CrossRef114
Roy A. Jensen, David L. Page. (2003) Ductal Carcinoma In Situ of the Breast. The American Journal of Surgical Pathology 27:6, 828-831
CrossRef115
M. B. E. Menke-Pluymers. (2003) Chirurgische therapie: nieuwe ontwikkelingenchirurgie. Bijblijven 19:6, 233-237
CrossRef116
Jennifer K. Marshall, Kent A. Griffith, Bruce G. Haffty, Lawrence J. Solin, Frank A. Vicini, Beryl McCormick, David E. Wazer, Abram Recht, Lori J. Pierce. (2003) Conservative management of Paget disease of the breast with radiotherapy. Cancer 97:9, 2142-2149
CrossRef117
Fletcher, Suzanne W., Elmore, Joann G., . (2003) Mammographic Screening for Breast Cancer. New England Journal of Medicine 348:17, 1672-1680
Full Text118
Kefah Mokbel. (2003) Towards optimal management of ductal carcinoma in situ of the breast. European Journal of Surgical Oncology (EJSO) 29:2, 191-197
CrossRef119
Eileen Rakovitch, Edmee Franssen, John Kim, Ida Ackerman, Jean-Philippe Pignol, Lawrence Paszat, Kathleen I. Pritchard, Cindy Ho, Donald A. Redelmeier. (2003) A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer. Breast Cancer Research and Treatment 77:3, 285-293
CrossRef120
E. Shelley Hwang, Karen Kinkel, Laura J. Esserman, Ying Lu, Noel Weidner, Nola M. Hylton. (2003) Magnetic Resonance Imaging in Patients Diagnosed With Ductal Carcinoma-In-Situ: Value in the Diagnosis of Residual Disease, Occult Invasion, and Multicentricity. Annals of Surgical Oncology 10:4, 381-388
CrossRef121
Shelley Nakamura, Carol Woo, Howard Silberman, Oscar E Streeter, Bernard S Lewinsky, Melvin J Silverstein. (2002) Breast-conserving therapy for ductal carcinoma in situ: a 20-year experience with excision plus radiation therapy. The American Journal of Surgery 184:5, 403-409
CrossRef122
Veronesi, Umberto, Cascinelli, Natale, Mariani, Luigi, Greco, Marco, Saccozzi, Roberto, Luini, Alberto, Aguilar, Marisel, Marubini, Ettore, . (2002) Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer. New England Journal of Medicine 347:16, 1227-1232
Full Text123
Shabnam Jaffer, Ira J. Bleiweiss. (2002) Histologic classification of ductal carcinoma in situ. Microscopy Research and Technique 59:2, 92-101
CrossRef124
Dace Shugg, Victoria M. White, Paul R. B. Kitchen, Myee Pruden, John P. Collins, David J. Hill. (2002) Surgical management of ductal carcinoma in situ in Australia in 1995. ANZ Journal of Surgery 72:10, 708-715
CrossRef125
Kathryn A. Carolin, Samuel Tekyi-Mensah, Helen A. Pass. (2002) Lobular Carcinoma In Situ and Invasive Cancer: The Contralateral Breast Controversy. The Breast Journal 8:5, 263-268
CrossRef126
Janice K. Ryu. (2002) Radiotherapy for Breast Cancer: Today and Tomorrow. Cancer Biotherapy & Radiopharmaceuticals 17:3, 255-266
CrossRef127
Andrew C. Neuschatz, Thomas DiPetrillo, Margaret Steinhoff, Homa Safaii, Michael Yunes, Marcia Landa, Maureen Chung, Blake Cady, David E. Wazer. (2002) The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 94:7, 1917-1924
CrossRef128
Mary Ann Gilligan, Ronald T. Kneusel, Raymond G. Hoffmann, Ann L. Greer, Ann B. Nattinger. (2002) Persistent Differences in Sociodemographic Determinants of Breast Conserving Treatment Despite Overall Increased Adoption. Medical Care 40:3, 181-189
CrossRef129
Maureen A. Chung, David Wazer, Blake Cady. (2002) Contemporary management of breast cancer. Obstetrics and Gynecology Clinics of North America 29:1, 173-188
CrossRef130
Gordon Francis Schwartz, Daniela Terribile. (2002) The treatment of ductal carcinoma in situ of the breast. Obstetrics and Gynecology Clinics of North America 29:1, 189-200
CrossRef131
C. Tunon-de-Lara, I. de-Mascarel, G. Mac-Grogan, E. Stöckle, O. Jourdain, V. Acharian, C. Guegan, A. Faucher, E. Bussieres, M. Trojani, F. Bonichon, B. Barreau, M. H. Dilhuydy, J. M. Dilhuydy, L. Mauriac, M. Durand, A. Avril. (2001) Analysis of 676 Cases of Ductal Carcinoma in Situ of the Breast From 1971 to 1995. American Journal of Clinical Oncology 24:6, 531-536
CrossRef132
Monica Morrow. (2001) Treatment selection in ductal carcinomain situ. Breast Cancer 8:4, 275-282
CrossRef133
D. Elling, A.S. Vesper, B. Fiedler, H. Martin, J. Krocker. (2001) Intraductal component in invasive breast cancer: analysis of 250 resected surgical specimens. The Breast 10:5, 405-410
CrossRef134
Hiram S. Cody, Nancy Klauber-DeMore, Patrick I. Borgen, Kimberly J. Zee. (2001) Is It Really Duct Carcinoma In Situ?. Annals of Surgical Oncology 8:8, 617-617
CrossRef135
Naomi A. Miller, Judy-Anne Chapman, Edward B. Fish, Marilyn A. Link, Eve Fishell, Barbara Wright, H. Lavina A. Lickley, David R. McCready, Wedad M. Hanna. (2001) In Situ Duct Carcinoma of the Breast: Clinical and Histopathologic Factors and Association with Recurrent Carcinoma. The Breast Journal 7:5, 292-302
CrossRef136
M.K Jha, V.S Avlonitis, C.D.M Griffith, T.W.J Lennard, R.G Wilson, L.M McLean, P.D Dawes, J Shrimankar. (2001) Aggressive local treatment for screen-Èdetected DCIS results in very low rates of recurrence. European Journal of Surgical Oncology (EJSO) 27:5, 454-458
CrossRef137
Mario Schootman, Rebecca Aft. (2001) Rural-urban differences in radiation therapy for ductal carcinoma in-situ of the breast. Breast Cancer Research and Treatment 68:2, 117-125
CrossRef138
Louise Bordeleau, Eileen Rakovitch, David M. Naimark, Kathleen I. Pritchard, Ida Ackerman, Carol A. Sawka. (2001) A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92:1, 23-29
CrossRef139
Louise Bordeleau, Eileen Rakovitch, David M. Naimark, Kathleen I. Pritchard, Ida Ackerman, Carol A. Sawka. (2001) A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92:1, 23-29
CrossRef140
Louise Bordeleau, Eileen Rakovitch, David M. Naimark, Kathleen I. Pritchard, Ida Ackerman, Carol A. Sawka. (2001) A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92:1, 23-29
CrossRef141
Louise Bordeleau, Eileen Rakovitch, David M. Naimark, Kathleen I. Pritchard, Ida Ackerman, Carol A. Sawka. (2001) A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92:1, 23-29
CrossRef142
Louise Bordeleau, Eileen Rakovitch, David M. Naimark, Kathleen I. Pritchard, Ida Ackerman, Carol A. Sawka. (2001) A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92:1, 23-29
CrossRef143
Louise Bordeleau, Eileen Rakovitch, David M. Naimark, Kathleen I. Pritchard, Ida Ackerman, Carol A. Sawka. (2001) A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer 92:1, 23-29
CrossRef144
Elizabeth B. Claus, Peiguo Chu, Christine L. Howe, Tracey L. Davison, David F. Stern, Darryl Carter, Michael P. DiGiovanna. (2001) Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors. Experimental and Molecular Pathology 70:3, 303-316
CrossRef145
Thomas B. Julian. (2001) MRI: A role in clinical trials. Journal of Magnetic Resonance Imaging 13:6, 837-841
CrossRef146
S Stallard, D.A Hole, A.D Purushotham, L.Y Hiew, H Mehanna, C Cordiner, H Dobson, E.A Mallon, W.D George. (2001) Ductal carcinoma in situ of the breast – among factors predicting for recurrence, distance from the nipple is important. European Journal of Surgical Oncology (EJSO) 27:4, 373-377
CrossRef147
Graham Giles, Ian Russell, Richard Reed, Georgina Marr, Anne Kavanagh. (2001) In situ and small invasive breast cancer register in Victoria, 1988 to 1992: Tumour characteristics and patient management. ANZ Journal of Surgery 71:5, 266-270
CrossRef148
Peter Malycha. (2001) Collation of Australasian data regarding breast cancer. ANZ Journal of Surgery 71:5, 265-265
CrossRef149
Shyr-Ming Sheen-Chen, Han-Shiang Chen, Wei-Jen Chen, Hock-Liew Eng, Chih-Wei Sheen, Fong-Fu Chou. (2001) Paget disease of the breast?an easily overlooked disease?. Journal of Surgical Oncology 76:4, 261-265
CrossRef150
N. Bijker, E.J.T. Rutgers, J.L. Peterse, I.S. Fentiman, J.-P. Julien, L. Duchateau, J.A. van Dongen. (2001) Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. European Journal of Surgical Oncology (EJSO) 27:2, 135-140
CrossRef151
Melvin J Silverstein, Steve Parker, James C Grotting, Richard J Cote, Christy A Russell. (2001) Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies11No competing interests declared.. Journal of the American College of Surgeons 192:2, 196-214
CrossRef152
Nina Bijker, Emiel J.T. Rutgers, Luc Duchateau, Johannes L. Peterse, Jean-Pierre Julien, Luigi Cataliotti, . (2001) Breast-conserving therapy for paget disease of the nipple. Cancer 91:3, 472-477
CrossRef153
Qun Zhou, Torsten Hopp, Suzanne A.W Fuqua, Patricia S Steeg. (2001) Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Letters 162:1, 3-17
CrossRef154
Kai C. Chan, W. Fiona Knox, Guria Sinha, Ashu Gandhi, Lester Barr, Andrew D. Baildam, Nigel J. Bundred. (2001) Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer 91:1, 9-16
CrossRef155
Jun Horiguchi, Yuichi lino, Hiroyuki Takei, Michio Maemura, Yukio Koibuchi, Yoshio Horii, Hiroshi Matsumoto, Takao Yokoe, Tetsunari Oyama, Takashi Nakajima, Yasuo Morishita. (2001) Recurrence of Breast Cancer following local excision alone for ductal carcinoma in situ. Breast Cancer 8:1, 52-57
CrossRef156
Michael D. Lagios, Melvin J. Silverstein. (2000) Outcomes and factors impacting local recurrence of ductal carcinoma in situ. Cancer 89:11, 2323-2324
CrossRef157
Debra M. Ikeda, Douglas R. Baker, Bruce L. Daniel. (2000) Magnetic resonance imaging of breast cancer: Clinical indications and breast MRI reporting system. Journal of Magnetic Resonance Imaging 12:6, 975-983
CrossRef158
Gordon F. Schwartz. (2000) The Role of Radiotherapy in Ductal Carcinoma in Situ of the Breast. The Breast Journal 6:5, 315-316
CrossRef159
Nadeem Q. Mirza, Georges Vlastos, Funda Meric, Aysegul A. Sahin, S. Eva Singletary, Lisa A. Newman, Henry M. Kuerer, Frederick C. Ames, Merrick I. Ross, Barry W. Feig, Raphael E. Pollock, Thomas A. Buchholz, Marsha D. McNeese, Eric A. Strom, Gabriel N. Hortobagyi, Kelly K. Hunt. (2000) Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy. Annals of Surgical Oncology 7:9, 656-664
CrossRef160
Barbara S. Schwartzberg, Jeffrey J. Goates, William E. Kelley. (2000) MINIMAL ACCESS BREAST SURGERY. Surgical Clinics of North America 80:5, 1383-1398
CrossRef161
Raymond J. Lanzafame. (2000) Surgical Evolution: Clinical Practice Catching up to Tumor Biology in Breast and Colon Cancer. Journal of Clinical Laser Medicine <html_ent glyph="@amp;" ascii="&"/> Surgery 18:4, 171-172
CrossRef162
Neal S. Goldstein, Larry Kestin, Frank Vicini. (2000) Intraductal Carcinoma of the Breast. The American Journal of Surgical Pathology 24:8, 1058-1067
CrossRef163
M.J. Silverstein. (2000) Not everyone with ductal carcinoma in situ of the breast treated with breast preservation needs post-excisional radiation therapy. The Breast 9:4, 189-193
CrossRef164
Stephen A. Feig. (2000) DUCTAL CARCINOMA IN SITU. Radiologic Clinics of North America 38:4, 653-668
CrossRef165
JP Julien, N Bijker, IS Fentiman, JL Peterse. (2000) Adjuvant radiotherapy for DCIS. The Lancet 355:9220, 2061-2066
CrossRef166
Jeremy Millar, Alan Rodger. (2000) Adjuvant radiotherapy for DCIS. The Lancet 355:9220, 2072
CrossRef167
Isabelle de Mascarel, Françoise Bonichon, Gäetan MacGrogan, Christine Tunon de Lara, Antoine Avril, Véronique Picot, Michel Durand, Louis Mauriac, Monique Trojani, Jean-Michel Coindre. (2000) Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examinated by serial macroscopic sectioning: Practical considerations. Breast Cancer Research and Treatment 61:2, 151-159
CrossRef168
Farid Moinfar, Yan-Gao Man, Gary L. Bratthauer, Manfred Ratschek, Fattaneh A. Tavassoli. (2000) Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (?clinging ductal carcinoma in situ?). Cancer 88:9, 2072-2081
CrossRef169
J.John Kim. (2000) Part V. Adjuvant therapies for ductal carcinoma in situ. Current Problems in Cancer 24:3, 164-174
CrossRef170
Claire M.B. Holloway. (2000) Part IV. Surgery for ductal carcinoma in situ. Current Problems in Cancer 24:3, 142-163
CrossRef171
Elaine Y. Weng, Guy J. F. Juillard, Robert G. Parker, Helena R. Chang, Jeffrey A. Gornbein. (2000) Outcomes and factors impacting local recurrence of ductal carcinoma in situ. Cancer 88:7, 1643-1649
CrossRef172
G.H. Sakorafas, A.G.H. Tsiotou. (2000) Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives. Cancer Treatment Reviews 26:2, 103-125
CrossRef173
A Ringberg. (2000) Accrual rate-limiting factors in a Swedish randomised ductal carcinoma in situ (DCIS) trial — a demographic study. European Journal of Cancer 36:4, 483-488
CrossRef174
Melvin J. Silverstein. (2000) Ductal Carcinoma In Situ of the Breast. Annual Review of Medicine 51:1, 17-32
CrossRef175
Larry L. Kestin, Neal S. Goldstein, Mario D. Lacerna, Mamtha Balasubramaniam, Alvaro A. Martinez, Murray Rebner, Jane Pettinga, Robert C. Frazier, Frank A. Vicini. (2000) Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy. Cancer 88:3, 596-607
CrossRef176
Melvin J Silverstein, Michael D Lagios. (2000) Benefits of irradiation for DCIS: a Pyrrhic victory. The Lancet 355:9203, 510-511
CrossRef177
Jean-Pierre Julien, Nina Bijker, Ian S Fentiman, Johannes L Peterse, Vincenzo Delledonne, Philippe Rouanet, Antoine Avril, Richard Sylvester, Françoise Mignolet, Harry Bartelink, Joop A Van Dongen. (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. The Lancet 355:9203, 528-533
CrossRef178
Melvin J. Silverstein. (1999) Ductal Carcinoma In Situ of the Breast: A Surgeon?s Disease. Annals of Surgical Oncology 6:8, 802-810
CrossRef179
B Fisher. (1999) From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. European Journal of Cancer 35:14, 1963-1973
CrossRef180
Neal S. Goldstein, Larry Kestin, Frank Vicini. (1999) Pathologic Features of Initial Biopsy Specimens Associated With Residual Intraductal Carcinoma on Reexcision in Patients With Ductal Carcinoma In Situ of the Breast Referred for Breast-Conserving Therapy. The American Journal of Surgical Pathology 23:11, 1340
CrossRef181
Kimberly J. Van Zee, Laura Liberman, Billur Samli, Katherine N. Tran, Beryl McCormick, Jeanne A. Petrek, P. Peter Rosen, Patrick I. Borgen. (1999) Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery. Cancer 86:9, 1757-1767
CrossRef182
Alphonse G. Taghian, Simon N. Powell. (1999) THE ROLE OF RADIATION THERAPY FOR PRIMARY BREAST CANCER. Surgical Clinics of North America 79:5, 1091-1115
CrossRef183
E. Shelley Hwang, Laura J. Esserman. (1999) MANAGEMENT OF DUCTAL CARCINOMA IN SITU. Surgical Clinics of North America 79:5, 1007-1030
CrossRef184
R.J. Sutton, A. Singh, C.B. Baker, N.P.M. Sacks. (1999) Is mastectomy overtreatment for Paget's disease of the nipple?. The Breast 8:4, 191-194
CrossRef185
Edwin R. Fisher, James Dignam, Elizabeth Tan-Chiu, Joseph Costantino, Bernard Fisher, Soonmyung Paik, Norman Wolmark, . (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17. Cancer 86:3, 429-438
CrossRef186
Monica Morrow. (1999) Understanding ductal carcinoma in situ. Cancer 86:3, 375-377
CrossRef187
R Simmons. (1999) The evaluation of high risk and pre-invasive breast lesions and the decision process for follow up and surgical intervention. Surgical Oncology 8:2, 55-65
CrossRef188
Thelma C. Hurd, Stephen B. Edge, Morton S. Kahlenberg, Paul C. Stomper, Gary M. Proulx, Gary Schwartz, Vijay Khatri, Janet S. Winston. (1999) Treatment of early-stage breast cancer. Current Problems in Cancer 23:4, 149-228
CrossRef189
Bernard Fisher, James Dignam, Norman Wolmark, D Lawrence Wickerham, Edwin R Fisher, Eleftherios Mamounas, Roy Smith, Mirsada Begovic, Nikolay V Dimitrov, Richard G Margolese, Carl G Kardinal, Maureen T Kavanah, Louis Fehrenbacher, Robert H Oishi. (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. The Lancet 353:9169, 1993-2000
CrossRef190
James M. Metz, Lawrence J. Solin. (1999) Long-Term Outcome After Postmastectomy Radiation Therapy for the Treatment of Ductal Carcinoma in Situ of the Breast. American Journal of Clinical Oncology 22:3, 215-217
CrossRef191
Silverstein, Melvin J., Lagios, Michael D., Groshen, Susan, Waisman, James R., Lewinsky, Bernard S., Martino, Silvana, Gamagami, Parvis, Colburn, William J., . (1999) The Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the Breast. New England Journal of Medicine 340:19, 1455-1461
Full Text192
P Bonnier. (1999) Prognostic factors in ductal carcinoma in situ of the breast: results of a retrospective study of 575 cases. European Journal of Obstetrics & Gynecology and Reproductive Biology 84:1, 27-35
CrossRef193
Meg Adams-Cameron, Frank D. Gilliland, William C. Hunt M.A., Charles R. Key. (1999) Trends in incidence and treatment for ductal carcinoma in situ in Hispanic, American Indian, and non-Hispanic white women in New Mexico, 1973-1994. Cancer 85:5, 1084-1090
CrossRef194
Atilla Soran, Victor G. Vogel. (1999) Optimal Management of Primary Breast Cancer. The Breast Journal 5:2, 81-93
CrossRef195
Robert J. DeFatta, Elba A. Turbat-Herrera, Benjamin D.L. Li, William Anderson, Arrigo De Benedetti. (1999) Elevated expression of eIF4E in confined early breast cancer lesions: Possible role of hypoxia. International Journal of Cancer 80:4, 516-522
CrossRef196
John Boyages M.B.B.S., Geoff Delaney M.B.B.S., Richard Taylor M.B.B.S.. (1999) Predictors of local recurrence after treatment of ductal carcinoma in situ. Cancer 85:3, 616-628
CrossRef197
Stella Hetelekidis, Laura Collins, Barbara Silver, Judith Manola, Rebecca Gelman, Amiel Cooper, Susan Lester, Janice A. Lyons, Jay R. Harris, Stuart J. Schnitt. (1999) Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer 85:2, 427-431
CrossRef198
Snehal Bhoola, Patricia B. DeRose, Cynthia Cohen. (1999) Ductal Carcinoma In Situ of the Breast: Frequency of Biomarkers According to Histologic Subtype. Applied Immunohistochemistry & Molecular Morphology 7:2, 108-115
CrossRef199
Edward B. Fish, Judy-Anne W. Chapman, Naomi A. Miller, Marilyn A. Link, Eve Fishell, Barbara Wright, David R. McCready, George Y. Hiraki, Theodore M. Ross, Wedad M. Hanna, H. Lavina A. Lickley. (1998) Assessment of treatment for patients with primary ductal carcinoma in situ in the breast. Annals of Surgical Oncology 5:8, 724-732
CrossRef200
Carol J. Fabian, Bruce F. Kimler, Richard M. Elledge, William E. Grizzle, Samuel W. Beenken, John H. Ward. (1998) MODELS FOR EARLY CHEMOPREVENTION TRIALS IN BREAST CANCER. Hematology/Oncology Clinics of North America 12:5, 993-1017
CrossRef201
Robert T. Osteen. (1998) Limits of resection for ductal carcinoma in situ. Journal of Surgical Oncology 69:2, 63-65
CrossRef202
J.M. Dixon, D.L. Page. (1998) Ductal carcinoma in situ of the breast. The Breast 7:5, 239-242
CrossRef203
Daniel R Kollmorgen, Jay S Varanasi, Stephen B Edge, William E Carson. (1998) Paget’s disease of the breast: a 33-year experience. Journal of the American College of Surgeons 187:2, 171-177
CrossRef204
Sharona Even-Ram, Beatrice Uziely, Patrizia Cohen, Sorina Grisaru-Granovsky, Miriam Maoz, Yoav Ginzburg, Reuven Reich, Israel Vlodavsky, Rachel Bar-Shavit. (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Medicine 4:8, 909-914
CrossRef205
Silvia Franceschi, Fabio Levi, Carlo La Vecchia, Lalao Randimbison, Van-Cong Te. (1998) Second cancers followingin situ carcinoma of the breast. International Journal of Cancer 77:3, 392-395
CrossRef206
Sonal Pandya, Gasan Mackarem, Arthur K.C. Lee, Robert McLellan, Gerald J. Heatley, Kevin S. Hughes. (1998) Ductal Carcinoma In Situ: The Impact of Screening on Clinical Presentation and Pathologic Features. The Breast Journal 4:3, 146-151
CrossRef207
Nora Hansen, Monica Morrow. (1998) BREAST DISEASE. Medical Clinics of North America 82:2, 203-222
CrossRef208
W. Van den Bogaert. (1998) Breast cancer radiotherapy: is there still progression in the last decade of the twentieth century?. The Breast 7:1, 5-7
CrossRef209
Tadashi Ikeda, Futoshi Akiyama, Masahiro Hiraoka, Hideo Inaji, Noriaki Ohuchi, Yuichi Takatsuka, Masataka Yoshimoto. (1998) The current status of the treatment of ductal carcinoma in situ of japanese women, especially breast conserving operation in relation to the surgical margin and short term outcome. Breast Cancer 5:1, 53-58
CrossRef210
M. Deutsch, M.M. Rosenstein. (1998) Ductal carcinoma in situ (DCIS) of the male breast treated by lumpectomy and breast irradiation. Clinical Oncology 10:3, 204-205
CrossRef211
Lori J. Pierce, Bruce G. Haffty, Lawrence J. Solin, Beryl McCormick, Frank A. Vicini, David E. Wazer, Abram Recht, Myla Strawderman, Allen S. Lichter. (1997) The conservative management of Paget's disease of the breast with radiotherapy. Cancer 80:6, 1065-1072
CrossRef212
Barbara Fowble. (1997) The Results of Conservative Surgery and Radiation for Mammographically Detected Ductal Carcinoma In Situ. The Breast Journal 3:5, 238-241
CrossRef213
Melvin J. Silverstein. (1997) Ductal Carcinoma In Situ of the Breast: The Van Nuys Experience by Treatment. The Breast Journal 3:5, 232-237
CrossRef214
Richard L. Solit, Gordon F. Schwartz. (1997) Managed Care Managing Breast Cancer: DCIS as the Paradigm (The Fox Is Guarding the Chickencoop!). The Breast Journal 3:5, 303-307
CrossRef215
Eric R. Frykberg. (1997) An Overview of the History and Epidemiology of Ductal Carcinoma In Situ of the Breast. The Breast Journal 3:5, 227-231
CrossRef216
M Amichetti. (1997) Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy. European Journal of Cancer 33:10, 1559-1565
CrossRef217
Michael Reiss, Mary Helen Barcellos-Hoff. (1997) Transforming growth factor-β in breast cancer: A working hypothesis. Breast Cancer Research and Treatment 45:1, 81-95
CrossRef218
R.J. Salmon, B. Asselain, M. Le Gal, A. Fourquet. (1997) Twelve years of experience of breast cancer at the Institut Curie: improvement of survival and value of screening mammographics. The Breast 6:4, 202-205
CrossRef219
Sangeeta Sharma, Arnold D.K. Hill, Enda W. McDermott, Niall J. O'Higgins. (1997) Ductal carcinoma in situ of the breast—current management. European Journal of Surgical Oncology (EJSO) 23:3, 191-197
CrossRef220
P. F. Steindorfer. (1997) Editorial. European Surgery 29:3, 109-110
CrossRef221
R. Jakesz. (1997) Eingeladener Kommentar zu: „Zur Inzidenz und Behandlung des duktalen Carcinoma in situ (DCIS) der Mamma in Österreich”. European Surgery 29:3, 137-141
CrossRef222
H. Hauser, P. Steindorfer. (1997) Therapeutische Aspekte des duktalen Carcinoma in situ (DCIS) der Brust. European Surgery 29:3, 132-133
CrossRef223
Melvin J. Silverstein, Andreas Barth. (1997) Use of primary breast carcinoma characteristics to predict lymph node metastases?reply. Cancer 79:10, 1862-1864
CrossRef224
Deena Damsky Dell. (1997) Common Questions About Ductal Carcinoma In Situ. American Journal of Nursing 97:5, 61-66
CrossRef225
Melvin J. Silverstein, Philip Beron, Bernard S. Lewinsky. (1997) Breast-Conserving Therapy for Ductal Carcinoma in Situ: The Van Nuys Experience with Excision Plus Radiation Therapy. The Breast Journal 3:s1, 36-41
CrossRef226
Edwin R. Fisher. (1997) Lumpectomy margins and much more. Cancer 79:8, 1453-1458
CrossRef227
Geoff Delaney, Owen Ung, Stephen Cahill, Michael Bilous, John Boyages. (1997) DUCTAL CARCINOMA IN SITU PART 2: TREATMENT. ANZ Journal of Surgery 67:4, 157-165
CrossRef228
Xi Peng Yin, Xiao Qing Li, Duncan Neuhauser, James T. Evans. (1997) Assessment of Surgical Operations for Ductal Carcinoma In Situ of the Breast. International Journal of Technology Assessment in Health Care 13:03, 420
CrossRef229
Laurel A. Habel, Roger E. Moe, Janet R. Daling, Sarah Holte, Mary Anne Rossing, Noel S. Weiss. (1997) Risk of Contralateral Breast Cancer Among Women with Carcinoma In Situ of the Breast. Annals of Surgery 225:1, 69-75
CrossRef230
Colin M. Furnival. (1997) BREAST CANCER: CURRENT ISSUES IN DIAGNOSIS AND TREATMENT. ANZ Journal of Surgery 67:1, 47-58
CrossRef231
K. Mokbel, H. Kazkaz. (1996) The role of radiotherapy in pure Paget's disease of the breast. The Breast 5:6, 443
CrossRef232
A.J. Karayiannakis, E.A. Bastounis, E.B. Chatzigianni, G.G. Makri, D. Alexiou, P. Karamanakos. (1996) Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast. European Journal of Surgical Oncology (EJSO) 22:6, 578-582
CrossRef233
Edwin R. Fisher, Joseph Costantino, Bernard Fisher, Alka S. Palekar, S. M. Paik, C. M. Suarez, Norman Wolmark, . (1996) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17: Five-year observations concerning lobular carcinoma in situ. Cancer 78:7, 1403-1416
CrossRef234
WANDA W. YOUNG, STANLEY M. MARKS, SUSAN A. KOHLER, ANGEL Y. HSU. (1996) Dissemination of Clinical Results. Medical Care 34:10, 1003-1017
CrossRef235
Michele Y. Halyard, Gordon L. Grado, Paula J. Schomberg, Amy L. Weaver, Clive S. Grant, Thomas M. Pisansky. (1996) Conservative Therapy of Breast Cancer. American Journal of Clinical Oncology 19:5, 445-450
CrossRef236
K. Mokbel, H. Kazkaz, J. Glee. (1996) Paget's disease of the nipple. The Breast 5:5, 386-387
CrossRef237
Melvin J. Silverstein, Pamela H. Craig, Michael D. Lagios, James R. Waisman, Bernard S. Lewinsky, William J. Colburn, David N. Poller. (1996) Developing a prognostic index for ductal carcinoma in situ of the breast: Are we there yet?. Cancer 78:5, 1138-1140
CrossRef238
Mark S. Talamonti. (1996) Management of ductal carcinoma in situ. Seminars in Surgical Oncology 12:5, 300-313
CrossRef239
Erna Busch, Margaret Kemeny, Amy Fremgen, Robert T. Osteen, David P. Winchester, Rosemarie E. Clive. (1996) Patterns of breast cancer care in the elderly. Cancer 78:1, 101-111
CrossRef240
Melvin J. Silverstein, Michael D. Lagios, Pamela H. Craig, James R. Waisman, Bernard S. Lewinsky, William J. Colburn, David N. Poller. (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:11, 2267-2274
CrossRef241
Takashi Yamakawa, Mitsuaki Shinotoh, Toshikatsu Taniki, Osamu Yasuta, Masashi Hamagaki, Kan Kondoh, Akiyoshi Yamamoto, Satoshi Numoto, Sueyoshi Itoh, Mitsunori Sasa, Tadaoki Morimoto. (1996) Ductal carcinoma in situ of the breast: is breast conserving treatment feasible?. Breast Cancer 3:2, 119-123
CrossRef242
Stephan Bodis, Kalliopi P. Siziopikou, Stuart J. Schnitt, Jay R. Harris, David E. Fisher. (1996) Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 77:9, 1831-1835
CrossRef243
Bruce E. Hillner, Harry D. Bear, Laurie L. Fajardo. (1996) Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: A decision analysis model. Academic Radiology 3:4, 351-360
CrossRef244
Kevin S. Hughes, Arthur K. Lee, Ann Rolfs. (1996) CONTROVERSIES IN THE TREATMENT OF DUCTAL CARCINOMA IN SITU. Surgical Clinics of North America 76:2, 243-265
CrossRef245
Faek R. Jamali, Andrew Ricci, Peter J. Deckers. (1996) PAGET'S DISEASE OF THE NIPPLE-AREOLA COMPLEX. Surgical Clinics of North America 76:2, 365-381
CrossRef246
Morgan W. Nields. (1996) Cost-effectiveness of image-guided core needle biopsy versus surgery in diagnosing breast cancer. Academic Radiology 3, S138-S140
CrossRef247
Inaji Hideo, Koyama Hiroki, Motomura Kazuyoshi, Noguchi Shinzaburo. (1996) Differential distribution of ErbB-2 and pS2 proteins in ductal carcinomain situ of the breast. Breast Cancer Research and Treatment 37:1, 89-92
CrossRef248
(1996) Abstracts. Cancer Investigation 14:s1, 1-73
CrossRef249
Michael D. Lagios. (1996) Classification of duct carcinoma in situ (DCIS) with a characterization of high grade lesions: Defining cohorts for chemoprevention trials. Journal of Cellular Biochemistry 63:S25, 108-111
CrossRef250
Gordon F. Schwartz. (1996) Sub-Clinical Ductal Carcinoma In Situ of the Breast: Selection for Treatment by Local Excision and Surveillance Alone. The Breast Journal 2:1, 41-44
CrossRef251
Barbara Fowble. (1996) The Role of Radiotherapy in the Treatment of Ductal Carcinoma In Situ?The Challenge of the 1990s. The Breast Journal 2:1, 45-51
CrossRef252
Lynda G. Bobrow, Lisa C. Happerfield, Walter M. Gregory, Rosemary R. Millis. (1995) Ductal carcinomain situ: Assessment of necrosis and nuclear morphology and their association with biological markers. The Journal of Pathology 176:4, 333-341
CrossRef253
Mary-Jo Delvecchio Good. (1995) Cultural studies of biomedicine: An agenda for research. Social Science & Medicine 41:4, 461-473
CrossRef254
Raymond J. Lanzafame. (1995) Applications of laser technology in breast cancer therapy. Seminars in Surgical Oncology 11:4, 328-332
CrossRef255
Helen J. Stewart. (1995) Open randomized trials in the management of primary breast cancer. European Journal of Surgical Oncology (EJSO) 21:3, 233-237
CrossRef256
Nour Sneige, Marsha D McNeese, Edward N Atkinson, Frederick C Ames, Bonnie Kemp, Aysegul Sahin, Alberto G Ayala. (1995) Ductal carcinoma in situ treated with lumpectomy and irradiation: Histopathological analysis of 49 specimens with emphasis on risk factors and long term results. Human Pathology 26:6, 642-649
CrossRef257
F.A. Tavassoli, Y. Man. (1995) Morphofunctional Features of Intraductal Hyperplasia, Atypical Intraductal Hyperplasia, and Various Grades of Intraductal Carcinoma. The Breast Journal 1:3, 155-162
CrossRef258
Lori J. Pierce, Allen S. Lichter. (1995) Is Breast Irradiation Routinely Necessary Following Conservation Therapy of Breast Cancer?. The Breast Journal 1:3, 191-191
CrossRef259
Judith E. Karp, Vivian W. Pinn. (1995) Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research. The Breast Journal 1:3, 128-154
CrossRef260
David P. Winchester, Herman R. Menck, Robert T. Osteen, William Kraybill. (1995) Treatment trends for ductal carcinoma in situ of the breast. Annals of Surgical Oncology 2:3, 207-213
CrossRef261
David L. Page, Michael D. Lagios. (1995) Pathologic analysis of the national surgical adjuvant breast project (NSABP) B-17 trial. Unanswered questions remaining unanswered considering current concepts of ductal carcinoma in situ. Cancer 75:6, 1219-1222
CrossRef262
Edwin R. Fisher, Alka S. Palekar, Joseph Costantino, Bernard Fisher, Eleftherios Mamounas. (1995) Response—blunting the counterpoint. Cancer 75:6, 1223-1227
CrossRef263
Edwin R. Fisher, Joseph Costantino, Bernard Fisher, Alka S. Palekar, Carol Redmond. (1995) Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). Cancer 75:6, 1310-1319
CrossRef264
Michael D. Lagios. (1995) Ductal Carcinoma In Situ: Controversies in Diagnosis, Biology, and Treatment. The Breast Journal 1:2, 68-78
CrossRef265
Michael D. Lagios. (1995) Heterogeneity of duct carcinoma in situ (DCIS): Relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Letters 90:1, 97-102
CrossRef266
John W. Berg, Robert V. P. Hutter. (1995) Breast cancer. Cancer 75:S1, 257-269
CrossRef267
Kapil Dhingra. (1995) A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer. Journal of Cellular Biochemistry 59:S23, 19-24
CrossRef268
Robert Millikan, Lynn Dressler, Joseph Geradts, Mark Graham. (1995) The need for epidemiologic studies of in-situ carcinoma of the breast. Breast Cancer Research and Treatment 35:1, 65-77
CrossRef269
M.P. Vezeridis, K.I. Bland. (1994) Management of ductal carcinoma in situ. Surgical Oncology 3:6, 309-325
CrossRef270
David L. Page, Michael D. Lagios. (1994) Pathology and clinical evolution of ductal carcinoma in situ (DCIS) of the breast. Cancer Letters 86:1, 1-4
CrossRef271
(1994) The NSABP Trials. New England Journal of Medicine 331:12, 809-810
Full Text272
Mauricio G. Camus, Megha G. Joshi, Gasan Mackarem, Arthur K. C. Lee, Ricardo L. Rossi, J. Lawrence Munson, JO Buyske, Leonard J. Barbarisi, Laura E. Sanders, Kevin S. Hughes. (1994) Ductal carcinoma in situ of the male breast. Cancer 74:4, 1289-1293
CrossRef273
Melvin J. Silverstein, Eugene D. Gierson, Willia M. J. Colburn, Lise Morin Cope, Martin Furmanski, Gregory M. Senofsky, Parvis Gamagami, James R. Waisman. (1994) Can intraductal breast carcinoma be excised completely by local excision? Clinical and pathologic predictors. Cancer 73:12, 2985-2989
CrossRef274
Angell, Marcia, Kassirer, Jerome P., . (1994) Setting the Record Straight in the Breast-Cancer Trials. New England Journal of Medicine 330:20, 1448-1450
Full Text275
P.A. Holland, N.J. Bundred. (1994) The management of ductal carcinoma in situ. The Breast 3:1, 1-2
CrossRef276
Eric R. Frykberg, Kirby I. Bland. (1994) Management of in situ and minimally invasive breast carcinoma. World Journal of Surgery 18:1, 45-57
CrossRef277
Robert M. Cooper. (1994) Mastectomy from the perspective of a medical oncologist. Cancer 74:S1, 362-365
CrossRef278
Eric R. Frykberg, Kirby I. Bland. (1994) Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 74:S1, 350-361
CrossRef279
Bernard Fisher, Stewart Anderson. (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World Journal of Surgery 18:1, 63-69
CrossRef280
(1993) Radiation Therapy for in Situ or Localized Breast Cancer. New England Journal of Medicine 329:21, 1577-1579
Full Text281
Bernard Fisher. (1993) Contributions to the understanding and management of breast cancer. Steiner award lecture 1992. International Journal of Cancer 55:2, 179-180
CrossRef282
Swain, Sandra M., . (1993) In Situ or Localized Breast Cancer -- How Much Treatment Is Needed?. New England Journal of Medicine 328:22, 1633-1634
Full Text283
Michael D. Lagios. (1993) Heterogeneity of ductal carcinomain situ of the breast. Journal of Cellular Biochemistry 53:S17G, 49-52
CrossRef
- Letters
